**TDMS No.** 97008 - 05

Test Type: CHRONIC

Species/Strain: RATS/F 344

P18: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a)

WITH AVERAGE SEVERITY GRADES[b]

PROPARGYL ALCOHOL **CAS Number:** 107-19-7

Pathologist: HARBO, S. - LIEUALLEN, W.

Lab: BNW

Date Report Regsted: 08/09/2006

Time Report Regsted: 14:01:40

First Dose M/F: 10/01/01 / 10/01/01

F1\_R2

C Number: C97008

Route: RESPIRATORY EXPOSURE WHOLE BODY

Lock Date: 08/16/2004

**Cage Range:** ALL

**Date Range:** ALL

**Reasons For Removal:** 25021 TSAC 25020 NATD 25019 MSAC

**Removal Date Range:** ALL

**Treatment Groups:** Include ALL

b - Average severity grade (1-minimal; 2-mild; 3-moderate; 4-marked)

Species/Strain: RATS/F 344

Route: RESPIRATORY EXPOSURE WHOLE BODY

#### P18: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a) WITH AVERAGE SEVERITY GRADES[b]

PROPARGYL ALCOHOL

**CAS Number:** 107-19-7

Pathologist: HARBO, S. - LIEUALLEN, W.

Date Report Regsted: 08/09/2006

Time Report Reqsted: 14:01:40 First Dose M/F: 10/01/01 / 10/01/01

FISCHER 344 RATS MALE	CONTROL	16 PPM	32 PPM	64 PPM
Disposition Summary				
Animals Initially in Study	50	50	50	50
Early Deaths				
Moribund Sacrifice	20	19	26	30
Natural Death	2	8	9	4
Survivors				
Moribund Sacrifice	1			
Terminal Sacrifice	26	23	15	16
Animals Examined Microscopically	49	50	50	50
ALIMENTARY SYSTEM				
Intestine Large, Colon	(47)	(46)	(45)	(49)
Artery, Inflammation, Chronic Active	1 [2.0]	(15)	(1-)	(1-)
Intestine Large, Rectum	(47)	(47)	(46)	(50)
Edema	1 [3.0]	, ,	. ,	, ,
Inflammation, Suppurative	1 [1.0]			
Intestine Small, Jejunum	(46)	(45)	(45)	(48)
Liver	(49)	(50)	(50)	(50)
Angiectasis	1 [1.0]	3 [2.3]		
Basophilic Focus	7	18	15	4
Clear Cell Focus	10	13	9	4
Degeneration, Cystic	3 [1.7]	1 [2.0]	1 [2.0]	2 [2.0]
Eosinophilic Focus Hematopoietic Cell Proliferation	2	4	2	5
Hemorrhage	1 [1.0]	1 [2.0]	1 [2.0] 1 [3.0]	
Hepatodiaphragmatic Nodule		5 [4.0]	1 [3.0] 2 [4.0]	1 [4.0]
Inflammation, Granulomatous		J [4.0]	2 [4.0] 1 [2.0]	ı [ <del>4</del> .0]
Inflammation, Chronic Active	1 [2.0]		1 [2.0]	
Mixed Cell Focus	2	4	5	3
Necrosis	1 [1.0]	2 [2.0]	2 [3.0]	2 [2.5]
Vacuolization Cytoplasmic	7 [2.9]	5 [2.6]	3 [2.7]	3 [3.3]
Centrilobular, Degeneration	1 [2.0]			1 [3.0]
Hepatocyte, Regeneration				2 [3.5]
Mesentery	(11)	(14)	(7)	(3)
Necrosis	10 [2.9]	14 [3.0]	7 [3.0]	2 [3.0]
Thrombosis				1 [4.0]

a - Number of animals examined microscopically at site and number of animals with lesion b - Average severity grade (1-minimal; 2-mild; 3-moderate; 4-marked)

Species/Strain: RATS/F 344

Route: RESPIRATORY EXPOSURE WHOLE BODY

## P18: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a) WITH AVERAGE SEVERITY GRADES[b]

PROPARGYL ALCOHOL CAS Number: 107-19-7

Pathologist: HARBO, S. - LIEUALLEN, W.

Date Report Regsted: 08/09/2006

Time Report Reqsted: 14:01:40 First Dose M/F: 10/01/01 / 10/01/01

Heart (49) (50) (50) (50) (50) (50) (50) (50) (50						
Oral Mucosa (0) (1) (1) (1) (0) (2) Pancreas (49) (50) (50) (50) (50) (50) (50) (50) (50	FISCHER 344 RATS MALE	CONTROL	16 PPM	32 PPM	64 PPM	
Oral Mucosa (0) (1) (1) (1) (0) (2) Pancreas (49) (50) (50) (50) (50) (50) (50) (50) (50	Automor Inflamentation Channin Active	4 [2 0]				
Pancreas (49) (50) (50) (50) (50) Acinus, Atrophy 24 [2.0] 21 [1.9] 22 [2.1] 26 [1.9] Acinus, Hyperplasia 3 [3.3] 1 [2.0] 1 [2.0] 1 [2.0] Duct, Necrosis 1, [3.0] Salivary Glands (49) (50) (50) (50) (50) Stomach, Forestomach (49) (50) (50) (50) Edema 1 [3.0] Erosion 1 [3.0] 1 [1.0] Hyperplasia, Squamous 1 [3.0] 1 [1.0] Hyperplasia, Squamous 1 [3.0] 1 [2.0] Ulcer 1 [2.0] Ulcer 4 [3.0] 3 [2.0] 3 [2.0] Ulcer 4 [4.0] (50) (50) (50) Erosion 4 [2.0] 2 [2.0] 5 [2.0] 3 [2.0] Ulcer 5 [2.6] 1 [3.0] 4 [2.5] Ulcer 5 [2.6] 1 [3.0] 4 [2.5] Ulcer 5 [3.6] 1 [3.0] 4 [2.5] Ulcer 5 [3.6] 1 [3.0] 5 [2.0] 5 [2.0] 5 [2.0] Ulcer 5 [3.6] 1 [3.0] 5 [2.0] Ulcer 5 [3.6] 1 [3.0] 5 [2.0] 5 [2.0] Ulcer 5 [3.6] 1 [3.0] 5 [3.0] Ulcer 7 [3.6] 1 [3.0] 7 [3.0] 7 [3.0] Ulcer 7 [3.6] 1 [3.0] 7 [3.0] 7 [3.0] Ulcer 7 [3.6] 1 [3.0] 7 [3.0] 7 [3.0] Ulcer 7 [3.6] 1 [3.0] 7 [3.0] 7 [3.0] Ulcer 7 [3.6] 1 [3.0] 7 [3.0] 7 [3.0] Ulcer 7 [3.6] 1 [3.0] Ulcer 7 [3.0] 1 [3.0] Ulcer 7 [3.0] 1 [3.0] Ulcer		1 [3.0]	(4)	(1)	(0)	
Acinus, Atrophy Acinus, Hyperplasia 3 [3.3] 1 [2.0] 1 [2.0] 1 [2.0] Duct, Necrosis 3 [3.3] 1 [2.0] 1 [2.0] 1 [2.0] Duct, Necrosis 3 [3.3] 1 [2.0] 1 [3.0] Sluray, Glands (49) (50) (50) (50) Edema 1 [3.0] 1 [3.0] Edema 1 [3.0] 1 [1.0] Hyperplasia, Squamous Inflammation, Chronic Ulcer 4 [3.0] 3 [2.0] 3 [2.0] Ulcer 4 [2.0] 2 [2.0] 5 [2.0] 3 [2.3] Ulcer 5 [2.6] Tongue (1) (0) (2) (1)  CARDIOVASCULAR SYSTEM  Heart (49) (50) (50) (50) (50) Cardiomyopathy 44 [1.7] 44 [2.1] 44 [2.2] 45 [2.1] Afrium, Thrombosis 3 [3.7] 6 [3.2] 8 [3.0]  ENDOCRINE SYSTEM  Adrenal Cortex (49) (50) (50) (50) Degeneration, Cystic 1 [4.0] Hyperplasia 19 [1.8] 23 [2.1] 27 [2.1] 28 [1.9] Hypertrophy 1 [2.0] Thrombosis 1 [2.0] Thrombosis 1 [2.1] 8 [1.8] 9 [2.0] 7 [1.4] Subcapsular, Hyperplasia 1 [1.0] Hyperplasia 1 [1.0] Hyperplasia 1 [2.1] 8 [1.8] 9 [2.0] 7 [1.4] Subcapsular, Hyperplasia 1 [1.0] Hyperplasia 1 [2.1] 8 [1.8] 9 [2.0] 7 [1.4] Subcapsular, Hyperplasia 1 [1.0] Hyperplasia 1 [2.1] 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1		(0)	(T) (EO)	(1) (50)	(U) (EO)	
Acinus, Hyperplasia 3 [3.3] 1 [2.0] 1						
Duct, Necrosis   13.0    50   50   50   50   50   50   50						
Salivary Glands (49) (50) (50) (50) (50) (50) (50) Stomach, Forestomach (49) (50) (50) (50) (50) (50) (50) (50) (50		၁ [၁.၁]	1 [2.0]		1 [2.0]	
Stomach, Forestomach   (49)   (50)   (50)   (50)   (50)     Edema		(40)	(50)		(FO)	
Edema 1 [3.0]				(50)		
Erosion			(50)	(50)	(50)	
Hyperplasia, Squamous   3 [2.0]   3 [2.0]   1 [2.0]		1 [3.0]	4 [2 0]		4 [4 0]	
Inflammation, Chronic			1 [3.0]	2 [2 0]	1 [1.0]	
Ulcer			3 [2.0]	3 [2.0] 4 [2.0]		
Stomach, Glandular	Innammation, Chronic	4 [2 0]	0.00		2 [2 5]	
Erosion 4 [2.0] 2 [2.0] 5 [2.0] 3 [2.3] Ulcer 5 [2.6] 1 [3.0] 4 [2.5] Tongue (1) (0) (2) (1)  CARDIOVASCULAR SYSTEM  Heart (49) (50) (50) (50) Cardiomyopathy 44 [1.7] 44 [2.1] 44 [2.2] 43 [2.1] Atrium, Thrombosis 3 [3.7] 6 [3.2] 8 [3.0] 5 [3.8]  ENDOCRINE SYSTEM  Adrenal Cortex (49) (50) (50) (50) Degeneration, Cystic 1 [4.0] Hematopoietic Cell Proliferation 1 [1.0] Hyperplasia 19 [1.8] 23 [2.1] 27 [2.1] 28 [1.9] Hypertrophy 1 [2.0] Thrombosis 1 [2.0] Vacuolization Cytoplasmic 11 [2.1] 8 [1.8] 9 [2.0] 7 [1.4] Subcapsular, Hyperplasia 15 [2.1] 19 [2.2] 21 [1.8] 18 [2.1] Infiltration Cellular, Lymphocyte 1 [1.0] Islets, Pancreatic (49) (50) (50) (50)		4 [3.0]				
Ulcer Tongue 5 [2.6] 1 [3.0] 4 [2.5] (1)  CARDIOVASCULAR SYSTEM  Heart (49) (50) (50) (50) (50) (50) (50) (50) (50						
Tongue (1) (0) (2) (1)  CARDIOVASCULAR SYSTEM  Heart (49) (50) (50) (50) Cardiomyopathy 44 [1.7] 44 [2.1] 44 [2.2] 43 [2.1] Atrium, Thrombosis 3 [3.7] 6 [3.2] 8 [3.0] 5 [3.8]  ENDOCRINE SYSTEM  Adrenal Cortex (49) (50) (50) (50) Degeneration, Cystic 1 [4.0] Hematopoietic Cell Proliferation 1 [1.0] Hyperplasia 19 [1.8] 23 [2.1] 27 [2.1] 28 [1.9] Hypertrophy 1 [2.0] Thrombosis 1 [2.0] Vacuolization Cytoplasmic 11 [2.1] 8 [1.8] 9 [2.0] 7 [1.4] Subcapsular, Hyperplasia 15 [2.1] 19 [2.2] 21 [1.8] 18 [2.1] Infiltration Cellular, Lymphocyte 1 [1.0] Islets, Pancreatic (49) (50) (50) (50)		4 [2.0] 5 [2.0]	2 [2.0]			
CARDIOVASCULAR SYSTEM  Heart (49) (50) (50) (50) (50) Cardiomyopathy 44 [1.7] 44 [2.1] 44 [2.2] 43 [2.1] Atrium, Thrombosis 3 [3.7] 6 [3.2] 8 [3.0] 5 [3.8]  ENDOCRINE SYSTEM  Adrenal Cortex (49) (50) (50) (50) Degeneration, Cystic 1 [4.0] Hematopoietic Cell Proliferation 1 [1.0] Hyperplasia 19 [1.8] 23 [2.1] 27 [2.1] 28 [1.9] Hypertrophy 1 [2.0] Thrombosis 1 [2.0] Vacuolization Cytoplasmic 11 [2.1] 8 [1.8] 9 [2.0] 7 [1.4] Subcapsular, Hyperplasia 1 [1.0] Adrenal Medulla (49) (50) (50) (50) (50) Infiltration Cellular, Lymphocyte 1 [1.0] Islets, Pancreatic (49) (50) (50) (50) (50)			(0)			
Heart (49) (50) (50) (50) (50) (50) (50) (50) (50	rongue	(1)	(0)	(2)	(1)	
Cardiomyopathy Atrium, Thrombosis  Adrenal Cortex Degeneration, Cystic Hematopoietic Cell Proliferation Hyperplasia Thrombosis  1 [2.0]  Vacuolization Cytoplasmic Subcapsular, Hyperplasia Adrenal Medulla Hyperplasia Adrenal Medulla Hyperplasia Adrenal Medulla Hyperplasia Hi [1.0] Hyperplasia H	CARDIOVASCULAR SYSTEM					
Cardiomyopathy Atrium, Thrombosis  Adrenal Cortex Degeneration, Cystic Hematopoietic Cell Proliferation Hyperplasia Thrombosis  1 [2.0]  Vacuolization Cytoplasmic Subcapsular, Hyperplasia Adrenal Medulla Hyperplasia Adrenal Medulla Hyperplasia Adrenal Medulla Hyperplasia Hi [1.0] Hyperplasia H	Heart	(49)	(50)	(50)	(50)	
Atrium, Thrombosis 3 [3.7] 6 [3.2] 8 [3.0] 5 [3.8]  ENDOCRINE SYSTEM  Adrenal Cortex (49) (50) (50) (50) Degeneration, Cystic 1 [4.0] Hematopoietic Cell Proliferation 1 [1.0] Hyperplasia 19 [1.8] 23 [2.1] 27 [2.1] 28 [1.9] Hypertrophy 1 [2.0] Thrombosis 1 [2.0] Vacuolization Cytoplasmic 11 [2.1] 8 [1.8] 9 [2.0] 7 [1.4] Subcapsular, Hyperplasia 1 [1.0] Adrenal Medulla (49) (50) (50) (50) Hyperplasia 15 [2.1] 19 [2.2] 21 [1.8] 18 [2.1] Infiltration Cellular, Lymphocyte 1 [1.0] Islets, Pancreatic (49) (50) (50) (50)	Cardiomyopathy					
Adrenal Cortex (49) (50) (50) (50)  Degeneration, Cystic 1 [4.0]  Hematopoietic Cell Proliferation 1 [1.0]  Hyperplasia 19 [1.8] 23 [2.1] 27 [2.1] 28 [1.9]  Hypertrophy 1 [2.0]  Thrombosis 1 [2.0]  Vacuolization Cytoplasmic 11 [2.1] 8 [1.8] 9 [2.0] 7 [1.4]  Subcapsular, Hyperplasia 1 [1.0]  Adrenal Medulla (49) (50) (50) (50)  Hyperplasia 15 [2.1] 19 [2.2] 21 [1.8] 18 [2.1]  Infiltration Cellular, Lymphocyte 1 [1.0]  Islets, Pancreatic (49) (50) (50) (50)						
Degeneration, Cystic 1 [4.0] Hematopoietic Cell Proliferation 1 [1.0] Hyperplasia 19 [1.8] 23 [2.1] 27 [2.1] 28 [1.9] Hypertrophy 1 [2.0] Thrombosis 1 [2.0] Vacuolization Cytoplasmic 11 [2.1] 8 [1.8] 9 [2.0] 7 [1.4] Subcapsular, Hyperplasia 1 [1.0] Adrenal Medulla (49) (50) (50) (50) Hyperplasia 15 [2.1] 19 [2.2] 21 [1.8] 18 [2.1] Infiltration Cellular, Lymphocyte 1 [1.0] Islets, Pancreatic (49) (50) (50) (50)	ENDOCRINE SYSTEM					
Hematopoietic Cell Proliferation       1 [1.0]         Hyperplasia       19 [1.8]       23 [2.1]       27 [2.1]       28 [1.9]         Hypertrophy       1 [2.0]       1 [2.0]         Thrombosis       1 [2.0]       7 [1.4]         Vacuolization Cytoplasmic       11 [2.1]       8 [1.8]       9 [2.0]       7 [1.4]         Subcapsular, Hyperplasia       1 [1.0]       (49)       (50)       (50)       (50)         Adrenal Medulla       (49)       (50)       (50)       (50)         Hyperplasia       15 [2.1]       19 [2.2]       21 [1.8]       18 [2.1]         Infiltration Cellular, Lymphocyte       1 [1.0]         Islets, Pancreatic       (49)       (50)       (50)       (50)	Adrenal Cortex		(50)	(50)	(50)	
Hyperplasia       19 [1.8]       23 [2.1]       27 [2.1]       28 [1.9]         Hypertrophy       1 [2.0]       1 [2.0]         Thrombosis       1 [2.0]       7 [1.4]         Vacuolization Cytoplasmic       11 [2.1]       8 [1.8]       9 [2.0]       7 [1.4]         Subcapsular, Hyperplasia       1 [1.0]       (49)       (50)       (50)       (50)         Adrenal Medulla       (49)       (50)       (50)       (50)         Hyperplasia       15 [2.1]       19 [2.2]       21 [1.8]       18 [2.1]         Infiltration Cellular, Lymphocyte       1 [1.0]         Islets, Pancreatic       (49)       (50)       (50)       (50)	Degeneration, Cystic	1 [4.0]				
Hypertrophy       1 [2.0]         Thrombosis       1 [2.0]         Vacuolization Cytoplasmic       11 [2.1]       8 [1.8]       9 [2.0]       7 [1.4]         Subcapsular, Hyperplasia       1 [1.0]         Adrenal Medulla       (49)       (50)       (50)       (50)         Hyperplasia       15 [2.1]       19 [2.2]       21 [1.8]       18 [2.1]         Infiltration Cellular, Lymphocyte       1 [1.0]         Islets, Pancreatic       (49)       (50)       (50)       (50)	Hematopoietic Cell Proliferation					
Hypertrophy       1 [2.0]         Thrombosis       1 [2.0]         Vacuolization Cytoplasmic       11 [2.1]       8 [1.8]       9 [2.0]       7 [1.4]         Subcapsular, Hyperplasia       1 [1.0]         Adrenal Medulla       (49)       (50)       (50)       (50)         Hyperplasia       15 [2.1]       19 [2.2]       21 [1.8]       18 [2.1]         Infiltration Cellular, Lymphocyte       1 [1.0]         Islets, Pancreatic       (49)       (50)       (50)       (50)	Hyperplasia	19 [1.8]	23 [2.1]	27 [2.1]	28 [1.9]	
Thrombosis 1 [2.0] Vacuolization Cytoplasmic 11 [2.1] 8 [1.8] 9 [2.0] 7 [1.4] Subcapsular, Hyperplasia 1 [1.0] Adrenal Medulla (49) (50) (50) (50) Hyperplasia 15 [2.1] 19 [2.2] 21 [1.8] 18 [2.1] Infiltration Cellular, Lymphocyte 1 [1.0] Islets, Pancreatic (49) (50) (50) (50)						
Vacuolization Cytoplasmic       11 [2.1]       8 [1.8]       9 [2.0]       7 [1.4]         Subcapsular, Hyperplasia       1 [1.0]         Adrenal Medulla       (49)       (50)       (50)       (50)         Hyperplasia       15 [2.1]       19 [2.2]       21 [1.8]       18 [2.1]         Infiltration Cellular, Lymphocyte       1 [1.0]         Islets, Pancreatic       (49)       (50)       (50)       (50)				1 [2.0]		
Subcapsular, Hyperplasia       1 [1.0]         Adrenal Medulla       (49)       (50)       (50)         Hyperplasia       15 [2.1]       19 [2.2]       21 [1.8]       18 [2.1]         Infiltration Cellular, Lymphocyte       1 [1.0]         Islets, Pancreatic       (49)       (50)       (50)       (50)	Vacuolization Cytoplasmic	11 [2.1]	8 [1.8]		7 [1.4]	
Adrenal Medulla       (49)       (50)       (50)       (50)         Hyperplasia       15 [2.1]       19 [2.2]       21 [1.8]       18 [2.1]         Infiltration Cellular, Lymphocyte       1 [1.0]         Islets, Pancreatic       (49)       (50)       (50)       (50)		1 [1.0]				
Hyperplasia       15 [2.1]       19 [2.2]       21 [1.8]       18 [2.1]         Infiltration Cellular, Lymphocyte       1 [1.0]         Islets, Pancreatic       (49)       (50)       (50)       (50)		(49)	(50)	(50)	(50)	
Infiltration Cellular, Lymphocyte 1 [1.0] Islets, Pancreatic (49) (50) (50) (50)	Hyperplasia					
Islets, Pancreatic (49) (50) (50) (50)	Infiltration Cellular, Lymphocyte					
	Islets, Pancreatic		(50)	(50)	(50)	
		1 [3.0]	5 [2.2]	1 [2.0]	1 [2.0]	

a - Number of animals examined microscopically at site and number of animals with lesion

b - Average severity grade (1-minimal; 2-mild; 3-moderate; 4-marked)

Species/Strain: RATS/F 344

Route: RESPIRATORY EXPOSURE WHOLE BODY

## P18: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a) WITH AVERAGE SEVERITY GRADES[b]

PROPARGYL ALCOHOL CAS Number: 107-19-7

Pathologist: HARBO, S. - LIEUALLEN, W.

Date Report Reqsted: 08/09/2006

Time Report Reqsted: 14:01:40
First Dose M/F: 10/01/01 / 10/01/01

FISCHER 344 RATS MALE	CONTROL	16 PPM	32 PPM	64 PPM	
Parathyroid Gland	(47)	(44)	(49)	(50)	
Hyperplasia		2 [1.5]			
Pituitary Gland	(49)	(50)	(50)	(50)	
Hemorrhage Pars Distalis, Hyperplasia	8 [2.6]	1 [2.0] 6 [2.3]	3 [4.0] 6 [1.7]	13 [2.3]	
Pars Intermedia, Cyst				1	
Thyroid Gland	(49)	(50)	(50)	(50)	
Cyst C-cell, Hyperplasia	8 [2.6]	6 [2.3]	15 [2.1]	12 [2.2]	
Follicular Cell, Hyperplasia	0 (2-10)	1 [3.0]	70 (201)	1 [2.0]	
ENERAL BODY SYSTEM					
Peritoneum	(1)	(0)	(0)	(0)	
Tissue NOS	(1)	(0)	(0)	(0)	
ENITAL SYSTEM					
Coagulating Gland	(0)	(0)	(1)	(0)	
Inflammation, Suppurative Epididymis	(49)	(50)	1 [3.0] (50)	(50)	
Penis	(0)	(0)	(0)	(1)	
Inflammation, Suppurative				1 [2.0]	
Preputial Gland Cyst	(49)	(49)	(50) 1	(49)	
Hyperplasia			'	2 [3.0]	
Inflammation, Chronic Active	18 [1.3]	12 [2.0]	11 [1.4]	12 [1.8]	
Necrosis Prostate	(49)	(50)	(50)	1 [3.0] (50)	
Hyperplasia	9 [2.0]	2 [2.0]	10 [2.0]	8 [2.0]	
Inflammation, Suppurative	31 [1.9]	41 [1.8]	36 [2.0]	34 [1.8]	
Inflammation, Chronic Active Seminal Vesicle	4 [2.8] (49)	(50)	1 [4.0] (50)	2 [3.0] (50)	
Hyperplasia	1 [3.0]				
Testes	(49)	(50)	(50)	(50)	
Germinal Epithelium, Atrophy Interstitial Cell, Hyperplasia	6 [3.8] 4 [2.0]	3 [3.3] 4 [1.8]	3 [3.3] 7 [1.7]	4 [3.5] 5 [1.6]	
· · · · · · · · · · · · · · · · · · ·	. []	. [ ]	. []	- []	

a - Number of animals examined microscopically at site and number of animals with lesion

b - Average severity grade (1-minimal; 2-mild; 3-moderate; 4-marked)

Species/Strain: RATS/F 344

Route: RESPIRATORY EXPOSURE WHOLE BODY

## P18: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a) WITH AVERAGE SEVERITY GRADES[b]

PROPARGYL ALCOHOL CAS Number: 107-19-7

Pathologist: HARBO, S. - LIEUALLEN, W.

Date Report Regsted: 08/09/2006

Time Report Reqsted: 14:01:40
First Dose M/F: 10/01/01 / 10/01/01

FISCHER 344 RATS MALE	CONTROL	16 PPM	32 PPM	64 PPM	
EMATOPOIETIC SYSTEM					
Bone Marrow	(49)	(50)	(50)	(50)	
Myelofibrosis		1 [2.0]			
Erythroid Cell, Hyperplasia		1 [3.0]	2 [3.5]	1 [4.0]	
Lymph Node	(5)	(3)	(7)	(8)	
Deep Cervical, Hemorrhage	1 [2.0]	1 [3.0]	1 [3.0]		
Deep Cervical, Hyperplasia, Lymphoid	1 [3.0]				
Pancreatic, Angiectasis	2 [3.5]			2 [3.0]	
Pancreatic, Infiltration Cellular, Histiocyte			1 [2.0]		
Lymph Node, Bronchial	(6)	(4)	(8)	(7)	
Angiectasis	1 [3.0]	. ,	2 [3.0]		
Hemorrhage	• •		1 [3.0]		
Hyperplasia, Lymphoid	1 [3.0]	2 [2.5]	1 [2.0]		
Lymph Node, Mandibular	(0)	(1)	(1)	(0)	
Hyperplasia, Lymphoid	( )	1 [2.0]	( )	( )	
Lymph Node, Mediastinal	(24)	(24)	(24)	(26)	
Angiectasis	( /	1 [3.0]	,	,	
Hemorrhage		1 [3.0]			
Hyperplasia, Lymphoid	3 [3.0]	1 [2.0]	3 [3.0]	2 [3.5]	
Infiltration Cellular, Histiocyte	1 [3.0]				
Inflammation, Chronic Active		1 [3.0]			
Lymph Node, Mesenteric	(49)	(50)	(50)	(49)	
Angiectasis	1 [1.0]	,	,	,	
Ectasia	1 [3.0]				
Hemorrhage	1 [3.0]				
Hyperplasia, Lymphoid	1 [3.0]		2 [4.0]		
Infiltration Cellular, Histiocyte	9 [2.1]	5 [2.0]	5 [2.6]	3 [2.3]	
Spleen	(49)	(50)	(49)	(49)	
Angiectasis	( /	,	1 [4.0]	,	
Hematopoietic Cell Proliferation	8 [3.0]	10 [2.1]	5 [3.0]	8 [2.9]	
Hemorrhage			1 [3.0]		
Hemorrhage, Chronic	1 [2.0]	3 [3.3]	2 [4.0]		
Hyperplasia, Lymphoid, Focal	1 [4.0]	F1	r - 1		
Hyperplasia, Lymphoid	r -1		2 [3.0]		
Infarct			1		
Thymus	(47)	(43)	(46)	(45)	
Cyst	( /	( /	( /	1	

a - Number of animals examined microscopically at site and number of animals with lesion

b - Average severity grade (1-minimal; 2-mild; 3-moderate; 4-marked)

Species/Strain: RATS/F 344

Route: RESPIRATORY EXPOSURE WHOLE BODY

## P18: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a) WITH AVERAGE SEVERITY GRADES[b]

PROPARGYL ALCOHOL CAS Number: 107-19-7

Pathologist: HARBO, S. - LIEUALLEN, W.

Date Report Reqsted: 08/09/2006

Time Report Reqsted: 14:01:40 First Dose M/F: 10/01/01 / 10/01/01

FISCHER 344 RATS MALE	CONTROL	16 PPM	32 PPM	64 PPM	
INTEGUMENTARY SYSTEM					
Mammary Gland Galactocele Inflammation, Suppurative Skin Cyst Epithelial Inclusion Ulcer Subcutaneous Tissue, Fibrosis Subcutaneous Tissue, Inflammation	(30)  1 [1.0]   (49) 2 [3.5] 5 [2.8] 1 [4.0] 1 [4.0]	(29) 1 [4.0] (50) 1 [4.0]	(28) 1 [4.0] (50) 3 [4.0] 2 [3.0]	(34) 3 [4.0] (50) 1 [3.0]	
MUSCULOSKELETAL SYSTEM  Bone Hyperostosis	(49)	(50) 1 [3.0]	(50) 1 [3.0]	(50)	
NERVOUS SYSTEM					
Brain Compression Hemorrhage Necrosis Thrombosis	(49) 10 [3.1] 1 [3.0]	(50) 9 [2.4] 1 [2.0] 1 [2.0]	(50) 18 [2.7] 3 [2.3] 1 [2.0]	(50) 9 [2.9] 2 [2.5] 2 [3.0] 1 [2.0]	
RESPIRATORY SYSTEM					
Larynx Foreign Body Inflammation, Chronic Active Metaplasia, Squamous Lung Foreign Body	(48) 2 3 [2.0] 1 [1.0] (49) 1	(50) 3 (50)	(50) 1 1 [3.0] (50)	(50)	
Hemorrhage Inflammation Thrombosis Alveolar Epithelium, Hyperplasia Alveolar Epithelium, Metaplasia, Squamous	8 [2.4] 2 [1.0]	1 [2.0] 1 [2.0] 12 [2.5] 1 [2.0]	3 [2.3] 1 [2.0] 11 [2.1]	2 [3.5] 2 [2.5] 1 [3.0] 7 [2.1] 1 [4.0]	

a - Number of animals examined microscopically at site and number of animals with lesion

b - Average severity grade (1-minimal; 2-mild; 3-moderate; 4-marked)

Species/Strain: RATS/F 344

Route: RESPIRATORY EXPOSURE WHOLE BODY

# P18: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a) WITH AVERAGE SEVERITY GRADES[b]

PROPARGYL ALCOHOL CAS Number: 107-19-7

Pathologist: HARBO, S. - LIEUALLEN, W.

Date Report Reqsted: 08/09/2006

Time Report Reqsted: 14:01:40
First Dose M/F: 10/01/01 / 10/01/01

FISCHER 344 RATS MALE	CONTROL	16 PPM	32 PPM	64 PPM	
Alveolus, Infiltration Cellular, Histiocyte	4 [1.8]	1 [2.0]		1 [2.0]	
Nose	(49)	(49)	(50)	(49)	
Foreign Body	`7 ′	`8 ´	`6 ´	`8 ´	
Hemorrhage				1 [2.0]	
Inflammation, Suppurative	1 [1.0]	1 [2.0]			
Inflammation, Chronic Active	9 [2.1]	12 [1.8]	22 [2.0]	28 [1.9]	
Glands, Olfactory Epithelium,				4 [1.8]	
Hyperplasia					
Glands, Respiratory Epithelium,	3 [1.3]	14 [1.3]	39 [1.6]	45 [1.9]	
Hyperplasia					
Olfactory Epithelium, Accumulation,		5 [1.0]	4 [1.3]	7 [1.6]	
Hyaline Droplet					
Olfactory Epithelium, Atrophy	1 [3.0]	21 [2.6]	26 [2.9]	26 [2.5]	
Olfactory Epithelium, Degeneration			1 [1.0]	7 [1.3]	
Olfactory Epithelium, Hyperplasia		1 [1.0]	3 [2.0]	5 [1.2]	
Olfactory Epithelium, Hyperplasia, Basal		19 [1.0]	42 [1.4]	42 [1.7]	
Cell		[]	[]	[]	
Olfactory Epithelium, Metaplasia,	1 [2.0]	10 [1.8]	18 [1.9]	29 [2.0]	
Respiratory	. [=1]	[]	[]	[]	
Olfactory Epithelium, Necrosis			2 [2.0]	6 [1.3]	
Respiratory Epithelium, Hyperplasia	5 [2.2]	21 [1.6]	44 [1.9]	42 [2.5]	
Respiratory Epithelium, Metaplasia,	2 [2.5]	2 [1.5]	2 [1.5]	4 [1.5]	
Squamous	2 [2.0]	2 [1.0]	2 [1.0]	1 [1.0]	
Pleura	(0)	(1)	(0)	(0)	
Tioura	(0)	(1)	(0)	(0)	
PECIAL SENSES SYSTEM					
Ear	(1)	(0)	(0)	(0)	
Eye	(49)	(50)	(50)	(50)	
Inflammation, Chronic Active	(10)	(00)	1 [1.0]	(66)	
Cornea, Mineralization	1 [1.0]		. []		
Lens, Cataract	1 [3.0]	3 [3.0]	2 [2.5]		
Zymbal's Gland	(0)	(1)	(0)	(0)	
Zymbar s Gland	(0)	(1)	(0)	(0)	
RINARY SYSTEM					
Kidney	(49)	(50)	(50)	(50)	
Cyst	1	2	3	(30)	
Infarct	1	1	2	2	
IIIIaiUl	ı	ı	2		

a - Number of animals examined microscopically at site and number of animals with lesion

b - Average severity grade (1-minimal; 2-mild; 3-moderate; 4-marked)

**TDMS No.** 97008 - 05 Test Type: CHRONIC

Species/Strain: RATS/F 344

Route: RESPIRATORY EXPOSURE WHOLE BODY

### P18: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a) WITH AVERAGE SEVERITY GRADES[b]

PROPARGYL ALCOHOL **CAS Number:** 107-19-7

Pathologist: HARBO, S. - LIEUALLEN, W.

Date Report Regsted: 08/09/2006

Time Report Reqsted: 14:01:40 First Dose M/F: 10/01/01 / 10/01/01

Lab: BNW

FISCHER 344 RATS MALE	CONTROL	16 PPM	32 PPM	64 PPM
Inflammation, Suppurative	1 [4.0]	2 [2.5]	2 [2.0]	1 [3.0]
Nephropathy, Chronic	42 [2.2]	47 [2.3]	48 [2.4]	48 [2.4]
Transitional Epithelium, Infarct			1	
Urinary Bladder	(49)	(50)	(50)	(50)
Edema				1 [2.0]
Inflammation, Chronic	1 [2.0]		1 [1.0]	
Transitional Epithelium, Hyperplasia	1 [1.0]			

\*\*\* END OF MALE \*\*\*

a - Number of animals examined microscopically at site and number of animals with lesion b - Average severity grade (1-minimal; 2-mild; 3-moderate; 4-marked)

Species/Strain: RATS/F 344

Route: RESPIRATORY EXPOSURE WHOLE BODY

#### P18: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a) WITH AVERAGE SEVERITY GRADES[b]

PROPARGYL ALCOHOL

**CAS Number:** 107-19-7

Pathologist: HARBO, S. - LIEUALLEN, W.

Date Report Regsted: 08/09/2006

Time Report Regsted: 14:01:40 First Dose M/F: 10/01/01 / 10/01/01

Animals Initially in Study 50 50 50 50 50 50 Early Deaths	FISCHER 344 RATS FEMALE	CONTROL	16 PPM	32 PPM	64 PPM
Early Deaths   Moribund Sacrifice   18	Disposition Summary				
Early Deaths   Moribund Sacrifice   18   16   19   19   19   Natural Death   3   3   3   4   5   5   5   5   5   5   5   5   5	Animals Initially in Study	50	50	50	50
Natural Death   Survivors   Natural Death   Terminal Sacrifice   29   30   27   26   26   29   30   27   26   26   29   30   27   26   26   27   26   27   26   27   26   27   26   27   26   27   26   27   27	Early Deaths				
Natural Death   1					19
Natural Death   Terminal Sacrifice   29   30   27   26		3	3	4	5
Terminal Sacrifice			1		
MENTARY SYSTEM   So		29		27	26
MENTARY SYSTEM					
Esophagus					
Intestine Large, Cecum     (48)     (48)     (47)     (46)       Ulcer     1 [3.0]     (48)     (47)     (46)       Serosa, Inflammation     1 [3.0]     (48)     (47)     (47)       Intestine Large, Colon     (48)     (48)     (47)     (47)       Serosa, Inflammation     1 [3.0]     (50)     (48)     (47)     (47)       Serosa, Inflammation     1 [3.0]     (48)     (48)     (46)     (46)       Intestine Small, Ileum     (48)     (48)     (47)     (46)       Intestine Small, Jejunum     (48)     (48)     (47)     (46)       Liver     (50)     (50)     (50)     (50)     (50)       Angiectasis     4 [2.5]     1 [1.0]     1 [3.0]       Basophilic Focus     6     6     7     7       Eosinophilic Focus     6     6     7     7       Eosinophilic Focus     1 [2.0]     2 [3.5]     5 [3.6]     2 [4.0]       Hepatodiaphragmatic Nodule     3 [4.0]     2 [3.5]     5 [3.6]     2 [4.0]       Inflammation, Chronic Active     1 [2.0]     2 [2.0]     1 [2.0]       Mixed Cell Focus     5     4     4     12       Necrosis     1 [3.0]     3 [2.3]     3 [2.3] <t< td=""><td>ALIMENTARY SYSTEM</td><td></td><td></td><td></td><td></td></t<>	ALIMENTARY SYSTEM				
Intestine Large, Cecum         (48)         (48)         (47)         (46)           Ulcer         1 [3.0]         Serosa, Inflammation         1 [3.0]           Intestine Large, Colon         (48)         (48)         (47)         (47)           Serosa, Inflammation         1 [3.0]         Intestine Small, Duodenum         (49)         (50)         (48)         (47)           Serosa, Inflammation         1 [3.0]         Intestine Small, Ileum         (48)         (48)         (46)         (46)           Intestine Small, Jejunum         (48)         (48)         (47)         (46)           Liver         (50)         (50)         (50)         (50)           Angiectasis         4 [2.5]         1 [1.0]         1 [3.0]           Basophilic Focus         3 7         36         40         31           Clear Cell Focus         6         6         7         7           Eosinophilic Focus         1 [2.0]         2 [3.5]         5 [3.6]         2 [4.0]           Hepatodiaphragmatic Nodule         3 [4.0]         2 [3.5]         5 [3.6]         2 [4.0]           Inflammation, Chronic Active         1 [2.0]         2 [2.0]         1 [2.0]           Mixed Cell Focus<	Esophagus	(50)	(50)	(50)	(50)
Serosa, Inflammation   1 [3.0]		(48)		(47)	(46)
Intestine Large, Colon     (48)     (48)     (47)     (47)       Serosa, Inflammation     1 [3.0]     Intestine Small, Duodenum     (49)     (50)     (48)     (48)     (48)     (48)     (48)     (48)     (48)     (48)     (48)     (48)     (48)     (48)     (48)     (47)     (46)       Intestine Small, Duodenum     (48)     (48)     (48)     (48)     (47)     (46)       Intestine Small, Duodenum     (48)     (47)     (46)       Intestine Small, Duodenum     (48)     (47)     (46)       Intestine Small, Ileum     (48)     (47)     (46)       Intestine Small, Ileum     (48)     (48)     (47)     (46)       Intestine Small, Ileum     (48)     (47)     (46)       Intestine Small, Ileum     (47)     (46)       Intestine Small, Ileum     (47)     (46)       Intestine Small, Ileum     (48)			1 [3.0]		
Serosa, Inflammation       1 [3.0]         Intestine Small, Duodenum       (49)       (50)       (48)       (47)         Serosa, Inflammation       1 [3.0]       (48)       (48)       (46)       (46)         Intestine Small, Ileum       (48)       (48)       (47)       (46)         Intestine Small, Jejunum       (48)       (48)       (47)       (46)         Liver       (50)       (50)       (50)       (50)         Angiectasis       4 [2.5]       1 [1.0]       1 [3.0]         Basophilic Focus       37       36       40       31         Clear Cell Focus       6       6       7       7         Eosinophilic Focus       2       3       3         Fibrosis       1 [2.0]       2 [3.5]       5 [3.6]       2 [4.0]         Inflammation, Granulomatous       1 [3.0]       2 [3.5]       5 [3.6]       2 [4.0]         Inflammation, Chronic Active       1 [2.0]       2 [2.0]       1 [2.0]         Mixed Cell Focus       5       4       4       12         Necrosis       1 [3.0]       2 [2.0]       2 [2.0]       2 [2.0]         Vacuolization Cytoplasmic       8 [2.0]       3 [2.3]       3 [2.3]		1 [3.0]			
Intestine Small, Duodenum Serosa, Inflammation     (49)     (50)     (48)     (47)       Serosa, Inflammation     1 [3.0]     (48)     (48)     (46)     (46)       Intestine Small, Ileum     (48)     (48)     (47)     (46)       Intestine Small, Jejunum     (48)     (48)     (47)     (46)       Liver     (50)     (50)     (50)     (50)     (50)       Angiectasis     4 [2.5]     1 [1.0]     1 [3.0]       Basophilic Focus     37     36     40     31       Clear Cell Focus     6     6     7     7       Eosinophilic Focus     6     6     7     7       Eosinophilic Focus     1 [2.0]     2 [3.5]     5 [3.6]     2 [4.0]       Inflammation, Granulomations     1 [3.0]     2 [3.5]     5 [3.6]     2 [4.0]       Inflammation, Granulomatous     1 [3.0]     2 [2.0]     1 [2.0]       Mixed Cell Focus     5     4     4     12       Necrosis     1 [3.0]     3 [2.3]     3 [2.3]     4 [2.3]       Vacuolization Cytoplasmic     8 [2.0]     3 [2.3]     3 [2.3]     4 [2.3]       Centrilobular, Necrosis     1 [3.0]     1 [3.0]     1 [3.0]			(48)	(47)	(47)
Serosa, Inflammation       1 [3.0]         Intestine Small, Ileum       (48)       (48)       (46)       (46)         Intestine Small, Jejunum       (48)       (48)       (47)       (46)         Liver       (50)       (50)       (50)       (50)         Angiectasis       1 [2.0]       1 [1.0]       1 [3.0]         Basophilic Focus       37       36       40       31         Clear Cell Focus       6       6       7       7         Eosinophilic Focus       2       3       3         Fibrosis       1 [2.0]       2 [3.5]       5 [3.6]       2 [4.0]         Hepatodiaphragmatic Nodule       3 [4.0]       2 [3.5]       5 [3.6]       2 [4.0]         Inflammation, Granulomatous       1 [3.0]       2 [2.0]       1 [2.0]         Mixed Cell Focus       5       4       4       12         Necrosis       1 [3.0]       2 [2.0]       2 [2.0]         Vacuolization Cytoplasmic       8 [2.0]       3 [2.3]       3 [2.3]       4 [2.3]         Centrilobular, Necrosis       1 [3.0]       1 [2.0]         Oval Cell, Hyperplasia       1 [1.0]       1 [1.0]			(50)	(40)	(47)
Intestine Small, Ileum       (48)       (48)       (46)       (46)         Intestine Small, Jejunum       (48)       (48)       (47)       (46)         Liver       (50)       (50)       (50)       (50)         Angiectasis       4 [2.5]       1 [1.0]       1 [3.0]         Basophilic Focus       37       36       40       31         Clear Cell Focus       6       6       7       7         Eosinophilic Focus       1 [2.0]       2       3       3         Fibrosis       1 [2.0]       1 [2.0]       5 [3.6]       2 [4.0]         Hepatodiaphragmatic Nodule Inflammation, Granulomatous       1 [3.0]       2 [2.0]       1 [2.0]         Inflammation, Chronic Active Mixed Cell Focus       5       4       4       12         Necrosis       1 [3.0]       2 [2.0]       2 [2.0]       2 [2.0]         Vacuolization Cytoplasmic Vacuolization Cytoplasmic Static Necrosis       8 [2.0]       3 [2.3]       3 [2.3]       4 [2.3]         Centrilobular, Necrosis Oval Cell, Hyperplasia       1 [3.0]       1 [3.0]       1 [3.0]			(50)	(48)	(47)
Intestine Small, Jejunum       (48)       (48)       (47)       (46)         Liver       (50)       (50)       (50)       (50)         Angiectasis       4 [2.5]       1 [1.0]       1 [3.0]         Basophilic Focus       37       36       40       31         Clear Cell Focus       6       6       7       7         Eosinophilic Focus       2       3       3         Fibrosis       1 [2.0]       2 [3.5]       5 [3.6]       2 [4.0]         Hepatodiaphragmatic Nodule       3 [4.0]       2 [3.5]       5 [3.6]       2 [4.0]         Inflammation, Granulomatous       1 [3.0]       2 [2.0]       1 [2.0]         Mixed Cell Focus       5       4       4       12         Necrosis       1 [3.0]       2 [2.0]       2 [2.0]         Vacuolization Cytoplasmic       8 [2.0]       3 [2.3]       3 [2.3]       4 [2.3]         Centrilobular, Necrosis       1 [3.0]       1 [2.0]         Oval Cell, Hyperplasia       1 [3.0]       1 [3.0]		1 [3.0] (48)	(48)	(46)	(46)
Liver       (50)       (50)       (50)       (50)       (50)         Angiectasis       4 [2.5]       1 [1.0]       1 [3.0]         Basophilic Focus       37       36       40       31         Clear Cell Focus       6       6       7       7         Eosinophilic Focus       2       3       3         Fibrosis       1 [2.0]       2 [3.5]       5 [3.6]       2 [4.0]         Inflammation, Granulomatous       1 [3.0]       2 [2.0]       1 [2.0]         Inflammation, Chronic Active       1 [2.0]       2 [2.0]       1 [2.0]         Mixed Cell Focus       5       4       4       12         Necrosis       1 [3.0]       2 [2.0]       2 [2.0]         Vacuolization Cytoplasmic       8 [2.0]       3 [2.3]       3 [2.3]       4 [2.3]         Centrilobular, Necrosis       1 [3.0]       1 [2.0]       1 [2.0]         Oval Cell, Hyperplasia       1 [1.0]       1 [1.0]			(48)		
Angiectasis       4 [2.5]       1 [1.0]       1 [3.0]         Basophilic Focus       37       36       40       31         Clear Cell Focus       6       6       7       7         Eosinophilic Focus       2       3       3         Fibrosis       1 [2.0]       5 [3.6]       2 [4.0]         Hepatodiaphragmatic Nodule       3 [4.0]       2 [3.5]       5 [3.6]       2 [4.0]         Inflammation, Granulomatous       1 [3.0]       2 [2.0]       1 [2.0]         Mixed Cell Focus       5       4       4       12         Necrosis       1 [3.0]       2 [2.0]       2 [2.0]         Vacuolization Cytoplasmic       8 [2.0]       3 [2.3]       3 [2.3]       4 [2.3]         Centrilobular, Necrosis       1 [3.0]       1 [2.0]       1 [2.0]         Oval Cell, Hyperplasia       1 [1.0]       1 [1.0]       1 [1.0]					
Basophilic Focus       37       36       40       31         Clear Cell Focus       6       6       7       7         Eosinophilic Focus       2       3       3         Fibrosis       1 [2.0]       5       3.6]       2 [4.0]         Hepatodiaphragmatic Nodule       3 [4.0]       2 [3.5]       5 [3.6]       2 [4.0]         Inflammation, Granulomatous       1 [3.0]       2 [2.0]       1 [2.0]         Mixed Cell Focus       5       4       4       12         Necrosis       1 [3.0]       2 [2.0]       2 [2.0]         Vacuolization Cytoplasmic       8 [2.0]       3 [2.3]       3 [2.3]       4 [2.3]         Centrilobular, Necrosis       1 [3.0]       1 [2.0]       1 [2.0]         Oval Cell, Hyperplasia       1 [1.0]       1 [1.0]       1 [1.0]		(00)			
Clear Cell Focus       6       6       7       7         Eosinophilic Focus       2       3       3         Fibrosis       1 [2.0]		37	36		31
Fibrosis       1 [2.0]         Hepatodiaphragmatic Nodule       3 [4.0]       2 [3.5]       5 [3.6]       2 [4.0]         Inflammation, Granulomatous       1 [3.0]       2 [2.0]       1 [2.0]         Inflammation, Chronic Active       1 [2.0]       2 [2.0]       1 [2.0]         Mixed Cell Focus       5       4       4       12         Necrosis       1 [3.0]       2 [2.0]         Vacuolization Cytoplasmic       8 [2.0]       3 [2.3]       3 [2.3]       4 [2.3]         Centrilobular, Necrosis       1 [3.0]       1 [2.0]         Oval Cell, Hyperplasia       1 [1.0]	Clear Cell Focus		6	7	7
Hepatodiaphragmatic Nodule       3 [4.0]       2 [3.5]       5 [3.6]       2 [4.0]         Inflammation, Granulomatous       1 [3.0]       2 [2.0]       1 [2.0]         Inflammation, Chronic Active       1 [2.0]       2 [2.0]       1 [2.0]         Mixed Cell Focus       5       4       4       12         Necrosis       1 [3.0]       2 [2.0]         Vacuolization Cytoplasmic       8 [2.0]       3 [2.3]       3 [2.3]       4 [2.3]         Centrilobular, Necrosis       1 [3.0]       1 [2.0]         Oval Cell, Hyperplasia       1 [1.0]			2	3	3
Inflammation, Granulomatous       1 [3.0]         Inflammation, Chronic Active       1 [2.0]       2 [2.0]       1 [2.0]         Mixed Cell Focus       5       4       4       12         Necrosis       1 [3.0]       2 [2.0]         Vacuolization Cytoplasmic       8 [2.0]       3 [2.3]       3 [2.3]       4 [2.3]         Centrilobular, Necrosis       1 [3.0]       1 [2.0]         Oval Cell, Hyperplasia       1 [1.0]					
Inflammation, Chronic Active       1 [2.0]       2 [2.0]       1 [2.0]         Mixed Cell Focus       5       4       4       12         Necrosis       1 [3.0]       2 [2.0]         Vacuolization Cytoplasmic       8 [2.0]       3 [2.3]       3 [2.3]       4 [2.3]         Centrilobular, Necrosis       1 [3.0]       1 [2.0]         Oval Cell, Hyperplasia       1 [1.0]	Hepatodiaphragmatic Nodule		2 [3.5]	5 [3.6]	2 [4.0]
Mixed Cell Focus       5       4       4       12         Necrosis       1 [3.0]       2 [2.0]         Vacuolization Cytoplasmic       8 [2.0]       3 [2.3]       3 [2.3]       4 [2.3]         Centrilobular, Necrosis       1 [3.0]       1 [2.0]         Oval Cell, Hyperplasia       1 [1.0]				0.70.01	4 [0 0]
Necrosis       1 [3.0]       2 [2.0]         Vacuolization Cytoplasmic       8 [2.0]       3 [2.3]       3 [2.3]       4 [2.3]         Centrilobular, Necrosis       1 [3.0]       1 [2.0]         Oval Cell, Hyperplasia       1 [1.0]			4		
Vacuolization Cytoplasmic       8 [2.0]       3 [2.3]       3 [2.3]       4 [2.3]         Centrilobular, Necrosis       1 [3.0]       1 [2.0]         Oval Cell, Hyperplasia       1 [1.0]		5		4	
Centrilobular, Necrosis 1 [3.0] 1 [2.0] Oval Cell, Hyperplasia 1 [1.0]		IO C1 8		3 [2 3]	
Oval Cell, Hyperplasia 1 [1.0]			ی [۲.۵]	رد.ك]	
		1 [0.0]			
(10)	Mesentery	(13)	(12)	(10)	(9)

a - Number of animals examined microscopically at site and number of animals with lesion b - Average severity grade (1-minimal; 2-mild; 3-moderate; 4-marked)

Species/Strain: RATS/F 344

Route: RESPIRATORY EXPOSURE WHOLE BODY

#### P18: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a) WITH AVERAGE SEVERITY GRADES[b]

PROPARGYL ALCOHOL **CAS Number:** 107-19-7

Pathologist: HARBO, S. - LIEUALLEN, W.

Date Report Regsted: 08/09/2006

Time Report Reqsted: 14:01:40 First Dose M/F: 10/01/01 / 10/01/01

FISCHER 344 RATS FEMALE	CONTROL	16 PPM	32 PPM	64 PPM	
Necrosis	13 [2.9]	12 [2.9]	10 [2.9]	9 [3.0]	
Oral Mucosa	(1)	(0)	(2)	(1)	
Foreign Body	1	(-)	1	( - /	
Ulcer			1 [3.0]		
Pancreas	(50)	(50)	(50)	(50)	
Inflammation	1 [4.0]	,	. ,	,	
Acinus, Atrophy	6 [1.8]	9 [1.6]	11 [1.8]	14 [1.5]	
Acinus, Inflammation, Chronic				1 [1.0]	
Salivary Glands	(50)	(50)	(50)	(50)	
Stomach, Forestomach	(50)	(50)	(50)	(50)	
Necrosis	,	,	. ,	1 [2.0]	
Ulcer	3 [2.7]	5 [2.8]	1 [3.0]	2 [2.5]	
Epithelium, Hyperplasia	1 [3.0]	1 [3.0]		1 [2.0]	
Serosa, Inflammation	1 [2.0]				
Stomach, Glandular	(49)	(50)	(50)	(48)	
Erosion	3 [2.0]	1 [2.0]	1 [2.0]	3 [1.7]	
Ulcer	1 [2.0]		1 [1.0]	1 [1.0]	
Serosa, Inflammation	1 [2.0]				
Tongue	(0)	(0)	(2)	(1)	
Inflammation, Granulomatous, Chronic	(-)	(-7	( )	1 [3.0]	
Active				[]	
Epithelium, Hyperplasia			1 [2.0]		
CARDIOVASCULAR SYSTEM					
Heart	(50)	(50)	(50)	(50)	
Cardiomyopathy	43 [2.0]		42 [2.0]	42 [2.1]	
Atrium, Thrombosis	43 [2.0] 2 [3.0]	45 [2.1]	42 [2.0] 2 [3.5]	42 [2.1] 4 [3.5]	
Athum, miombosis	2 [3.0]		2 [3.5]	4 [3.3 <u>]</u>	
ENDOCRINE SYSTEM					
Adrenal Cortex	(50)	(50)	(50)	(50)	
Angiectasis	3 [2.7]	(/	(,	()	
Degeneration, Cystic	- 1		1 [2.0]	2 [2.5]	
Hemorrhage				1 [2.0]	
Hyperplasia	28 [2.3]	23 [2.2]	22 [2.0]	21 [2.2]	
Necrosis	1 [4.0]	1 [3.0]			
Vacuolization Cytoplasmic	3 [2.0]	3 [2.3]	1 [3.0]	4 [2.3]	
Adrenal Medulla	(50)	(50)	(50)	(50)	

a - Number of animals examined microscopically at site and number of animals with lesion b - Average severity grade (1-minimal; 2-mild; 3-moderate; 4-marked)

Species/Strain: RATS/F 344

Route: RESPIRATORY EXPOSURE WHOLE BODY

#### P18: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a) WITH AVERAGE SEVERITY GRADES[b]

PROPARGYL ALCOHOL **CAS Number:** 107-19-7

Pathologist: HARBO, S. - LIEUALLEN, W.

Date Report Regsted: 08/09/2006

Time Report Reqsted: 14:01:40 First Dose M/F: 10/01/01 / 10/01/01

FISCHER 344 RATS FEMALE	CONTROL	16 PPM	32 PPM	64 PPM	
Hyperplasia	5 [2.0]	7 [1.7]	3 [1.3]	2 [1.5]	
Necrosis	1 [2.0]	. []	-[]	_[]	
Islets, Pancreatic	(50)	(50)	(50)	(50)	
Hyperplasia	1 [2.0]	4 [2.0]	4 [2.5]		
Parathyroid Gland	(49)	(47)	(50)	(47)	
Pituitary Gland	(50)	(50)	(50)	(50)	
Hemorrhage	1 [4.0]	5 [3.4]	2 [2.0]	3 [2.3]	
Pars Distalis, Cyst	4	2	3	0.10.61	
Pars Distalis, Hyperplasia Thyroid Gland	11 [2.5] (50)	5 [2.2] (50)	6 [2.0] (50)	9 [2.6] (50)	
C-cell, Hyperplasia	21 [2.1]	16 [2.3]	18 [1.9]	18 [2.4]	
ENERAL BODY SYSTEM  Tissue NOS Fat, Inflammation, Chronic	(1) 1 [2.0]	(0)	(1)	(0)	
GENITAL SYSTEM	(50)	(40)	(40)	(47)	
Clitoral Gland Cyst	(50) 1	(49)	(49) 1	(47)	
Hyperplasia	4 [2.3]	4 [2.3]	4 [2.0]	5 [2.4]	
Inflammation, Suppurative	7 [2.0]	4 [2.0]	1 [2.0]	1 [2.0]	
Inflammation, Chronic Active	8 [1.4]	4 [1.3]	9 [1.7]	5 [1.6]	
Ovary	(50)	(50)	(50)	(50)	
Cyst	6	5	6	8	
Inflammation	1 [4.0]				
Interstitial Cell, Hyperplasia	5 [2.8]	8 [2.8]	3 [2.7]	6 [2.8]	
Uterus	(50)	(50)	(50)	(50)	
Angiectasis Cyst			1 [3.0] 1		
Decidual Reaction			1 [4.0]		
Dilatation			1 [4.0]		
Fibrosis	1 [3.0]	1 [2.0]	[]	1 [2.0]	
Hemorrhage	1 [4.0]	2 [4.0]	3 [3.7]	1 [4.0]	
Inflammation, Chronic Active				1 [2.0]	
Endometrium, Hyperplasia, Cystic	3 [2.0]	3 [1.3]	8 [1.5]	5 [1.6]	

a - Number of animals examined microscopically at site and number of animals with lesion b - Average severity grade (1-minimal; 2-mild; 3-moderate; 4-marked)

Species/Strain: RATS/F 344

Route: RESPIRATORY EXPOSURE WHOLE BODY

#### P18: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a) WITH AVERAGE SEVERITY GRADES[b]

PROPARGYL ALCOHOL **CAS Number:** 107-19-7

Pathologist: HARBO, S. - LIEUALLEN, W.

Date Report Regsted: 08/09/2006

Time Report Regsted: 14:01:40 First Dose M/F: 10/01/01 / 10/01/01

FISCHER 344 RATS FEMALE	CONTROL	16 PPM	32 PPM	64 PPM
HEMATOPOIETIC SYSTEM				
Bone Marrow	(50)	(50)	(50)	(50)
Erythroid Cell, Hyperplasia	1 [3.0]	3 [3.0]	4 [3.0]	1 [3.0]
Lymph Node	(4)	(0)	(3)	(3)
Deep Cervical, Angiectasis			4 [0 0]	1 [3.0]
Pancreatic, Angiectasis Lymph Node, Bronchial	(4)	(2)	1 [2.0]	(10)
Angiectasis	(4)	(2)	(4) 1 [2.0]	(10) 1 [3.0]
Hyperplasia, Lymphoid			1 [2.0]	2 [2.0]
Lymph Node, Mediastinal	(29)	(27)	(30)	(25)
Angiectasis	(==)	(=, )	1 [4.0]	(20)
Hyperplasia, Lymphoid			1 [3.0]	
Infiltration Cellular, Histiocyte	1 [2.0]	1 [3.0]		
Lymph Node, Mesenteric	(49)	(50)	(49)	(50)
Angiectasis	1 [1.0]	1 [3.0]		1 [2.0]
Hemorrhage		1 [2.0]		
Hyperplasia, Lymphoid	2 [2.0]	0.50.41	0.50.01	4 [0 0]
Infiltration Cellular, Histiocyte	9 [2.0]	9 [2.1]	3 [2.0]	4 [2.0]
Spleen Accessory Spleen	(50) 1	(50)	(50)	(49)
Hematopoietic Cell Proliferation	21 [2.3]	26 [2.4]	22 [2.3]	17 [2.1]
Hemorrhage, Chronic	1 [4.0]	20 [2.4]	22 [2.5]	1 [4.0]
Capsule, Fibrosis	. [•]	1 [1.0]		1 [2.0]
Thymus	(46)	(45)	(47)	(48)
INITE OUNTENA DV OVOTENA				
INTEGUMENTARY SYSTEM				
Mammary Gland	(50)	(50)	(50)	(50)
Galactocele	2 [4.0]	1 [4.0]	2 [3.5]	1 [2.0]
Hyperplasia	1 [2.0]			
Inflammation, Chronic Active	1 [4.0]		4 [0 0]	4 [0.0]
Epithelium, Hyperplasia Skin	(50)	(50)	1 [2.0]	1 [2.0]
Cyst Epithelial Inclusion	(50) 1 [2.0]	(50)	(50)	(50) 1 [3.0]
Inflammation, Granulomatous	ı [2.0]			1 [3.0] 1 [2.0]
Ulcer	1 [4.0]	1 [2.0]	1 [3.0]	ا [ک.۷]
Subcutaneous Tissue, Hemorrhage	. []	. [=.0]	. [0.0]	1 [4.0]
Subcutaneous Tissue, Inflammation	1 [2.0]			

a - Number of animals examined microscopically at site and number of animals with lesion b - Average severity grade (1-minimal; 2-mild; 3-moderate; 4-marked)

Species/Strain: RATS/F 344

Route: RESPIRATORY EXPOSURE WHOLE BODY

# P18: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a) WITH AVERAGE SEVERITY GRADES[b]

PROPARGYL ALCOHOL CAS Number: 107-19-7

Pathologist: HARBO, S. - LIEUALLEN, W.

Date Report Reqsted: 08/09/2006

Time Report Reqsted: 14:01:40 First Dose M/F: 10/01/01 / 10/01/01

FISCHER 344 RATS FEMALE	CONTROL	16 PPM	32 PPM	64 PPM	
MUSCULOSKELETAL SYSTEM					
Bone	(50)	(50)	(50)	(50)	
Hyperostosis Nasal, Inflammation, Chronic Active		1 [3.0]		1 [2.0]	
Skeletal Muscle	(2)	(0)	(1)	(0)	
Fat, Necrosis	1 [3.0]	(-/	( )	(-7	
NERVOUS SYSTEM					
Brain	(50)	(50)	(50)	(50)	
Compression	6 [2.7]	11 [2.8]	4 [2.8]	9 [3.0]	
Hemorrhage	2 [2.0]	1 -1	,	2 [2.0]	
Inflammation, Suppurative				1 [2.0]	
Inflammation, Chronic Active	1 [3.0]			4.50.01	
Necrosis				1 [2.0]	
RESPIRATORY SYSTEM					
Larynx	(50)	(50)	(50)	(50)	
Foreign Body	2	3	2	6	
Inflammation, Chronic Active		1 [3.0]		3 [2.3]	
Metaplasia, Squamous	1 [2.0]	(==)	(==)	2 [3.0]	
Lung	(50)	(50)	(50)	(50)	
Foreign Body Hemorrhage			1 [2.0]	1	
Inflammation	1 [2.0]		1 [2.0]		
Inflammation, Suppurative	ا رکان			1 [4.0]	
Alveolar Epithelium, Hyperplasia	7 [1.7]	12 [2.2]	13 [1.8]	5 [1.6]	
Alveolar Epithelium, Metaplasia,	. []	[]	1 [2.0]	- []	
Squamous					
Alveolus, Infiltration Cellular, Histiocyte	3 [2.0]	3 [2.3]	1 [2.0]	2 [2.0]	
Nose	(49)	(49)	(50)	(50)	
Foreign Body	1	4	4	6	
Inflammation, Suppurative	7 [4 0]	0 [4 7]	1 [1.0]	40.[4.0]	
Inflammation, Chronic Active	7 [1.6]	9 [1.7]	11 [1.4]	18 [1.6]	
Epithelium, Nasolacrimal Duct,	1 [2.0]				

a - Number of animals examined microscopically at site and number of animals with lesion

b - Average severity grade (1-minimal; 2-mild; 3-moderate; 4-marked)

Species/Strain: RATS/F 344

Route: RESPIRATORY EXPOSURE WHOLE BODY

## P18: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a) WITH AVERAGE SEVERITY GRADES[b]

PROPARGYL ALCOHOL CAS Number: 107-19-7

Pathologist: HARBO, S. - LIEUALLEN, W.

Date Report Reqsted: 08/09/2006

Time Report Reqsted: 14:01:40
First Dose M/F: 10/01/01 / 10/01/01

FISCHER 344 RATS FEMALE	CONTROL	16 PPM	32 PPM	64 PPM	
Hyperplasia					
Glands, Olfactory Epithelium, Hyperplasia		6 [1.2]	1 [1.0]	2 [1.0]	
Glands, Respiratory Epithelium, Hyperplasia	2 [1.5]	33 [1.2]	44 [1.5]	47 [1.5]	
Nasolacrimal Duct, Inflammation, Chronic Active	3 [2.0]	1 [2.0]			
Olfactory Epithelium, Accumulation, Hyaline Droplet	6 [1.5]	5 [1.4]	6 [1.5]	15 [1.4]	
Olfactory Epithelium, Atrophy Olfactory Epithelium, Degeneration Olfactory Epithelium, Hyperplasia	3 [2.3]		28 [2.8] 1 [2.0]	37 [2.9] 4 [2.0] 1 [3.0]	
Olfactory Epithelium, Hyperplasia, Basal Cell		28 [1.0]	42 [1.6]	48 [1.9]	
Olfactory Epithelium, Metaplasia, Respiratory	3 [1.7]	2 [2.0]	7 [1.4]	17 [1.8]	
Olfactory Epithelium, Metaplasia, Squamous				1 [2.0]	
Olfactory Epithelium, Necrosis Respiratory Epithelium, Hyperplasia Respiratory Epithelium, Metaplasia, Squamous	2 [2.0]	23 [1.5] 1 [2.0]	2 [2.0] 25 [1.7]	5 [1.6] 36 [1.8] 4 [1.0]	
PECIAL SENSES SYSTEM					
Eye Inflammation, Suppurative	(49) 1 [1.0]	(50)	(50)	(50)	
Lens, Cataract Zymbal's Gland	4 [2.8] (0)	5 [3.0] (0)	8 [3.0] (2)	3 [2.3] (1)	
RINARY SYSTEM					
Kidney Infarct	(50) 1	(50) 1	(50)	(49) 1	
Inflammation, Suppurative Nephropathy, Chronic Bilateral, Hydronephrosis Pelvis, Transitional Epithelium, Hyperplasia	40 [1.8]	46 [1.9]	41 [1.7] 1 [2.0] 1 [2.0]	1 [2.0] 44 [1.7]	

a - Number of animals examined microscopically at site and number of animals with lesion

b - Average severity grade (1-minimal; 2-mild; 3-moderate; 4-marked)

**TDMS No.** 97008 - 05

Test Type: CHRONIC

Species/Strain: RATS/F 344

Route: RESPIRATORY EXPOSURE WHOLE BODY

### P18: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a) WITH AVERAGE SEVERITY GRADES[b]

PROPARGYL ALCOHOL **CAS Number:** 107-19-7

Pathologist: HARBO, S. - LIEUALLEN, W.

Date Report Regsted: 08/09/2006

Time Report Regsted: 14:01:40 First Dose M/F: 10/01/01 / 10/01/01

Lab: BNW

FISCHER 344 RATS FEMALE	CONTROL	16 PPM	32 PPM	64 PPM	
Urinary Bladder	(49)	(50)	(50)	(49)	

\*\*\* END OF REPORT \*\*\*

a - Number of animals examined microscopically at site and number of animals with lesion b - Average severity grade (1-minimal; 2-mild; 3-moderate; 4-marked)